Sponsors (115)
The bill strengthens federal authority, surveillance, and reporting to address xylazine supply and harms—potentially improving public-health and enforcement responses—but does so at the cost of increased criminalization risk, new burdens on legitimate medical and veterinary users, added agency and taxpayer costs, and transitional uncertainty.
Law enforcement, first responders, and public-health agencies can explicitly identify, schedule, remove, and track xylazine and its salts/isomers, improving surveillance and enabling targeted public-health and interdiction responses to xylazine-related harms.
Regular reporting requirements give federal, state, and local authorities a clearer evidence base on xylazine prevalence, diversion sources, and analogues, which can guide funding, public-health interventions, and interdiction priorities.
Transitional relief (short registration window, delayed labeling/packaging and distribution requirements, and grandfathering some manufacturers from immediate security upgrades) reduces sudden disruptions to lawful medical, veterinary, and supply-chain uses of xylazine and gives stakeholders time to comply.
People who use or possess xylazine-containing substances—especially low-income individuals and communities of color—face increased criminal penalties, arrests, and prosecutions as xylazine is treated and sentenced as a controlled substance.
Clinicians, veterinarians, animal-care providers, and hospitals will encounter tighter controls, new paperwork, and potential supply or access hurdles for legally using xylazine, raising compliance costs and risking interruptions in medical or veterinary care.
Broad, quantity-independent scheduling may push illicit markets to adulterate or substitute xylazine with other unknown substances, making overdoses harder to treat and complicating public-health responses.
Based on analysis of 7 sections of legislative text.
Defines and places xylazine into Schedule III, phases in regulatory requirements, directs sentencing review, and mandates federal reports on illicit xylazine.
Places xylazine (and its salts/isomers) into Schedule III of the Controlled Substances Act and makes related criminal‑justice, regulatory, and reporting changes. The bill adds a statutory definition of xylazine, treats any product or mixture containing xylazine as a Schedule III controlled substance, instructs the Sentencing Commission to review penalties for xylazine offenses, and requires federal reports on illicit xylazine trafficking and use. The bill also creates xylazine‑specific adjustments to the CSA’s "ultimate user" definition, delays or phases in certain Schedule III regulatory requirements for manufacturers and practitioners for short, specified periods, and directs DEA and FDA to facilitate the regulatory submissions and registrations triggered by the new scheduling designation.
Official title: To prohibit certain uses of xylazine, and for other purposes.
Introduced February 12, 2025 by James Varni Panetta · Last progress September 16, 2026